gemcitabine / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

130 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
NCT02959164: Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed
1b
36
US
Decitabine, Dacogen, Gemcitabine, Gemzar
Mohammed Milhem, Holden Comprehensive Cancer Center, University of Iowa
Pancreatic Ductal Adenocarcinoma, Sarcoma
09/19
10/20
MP-PDAC-01, NCT03666832: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel

Recruiting
1b
36
RoW
TEW-7197, TEW-7197, FOLFOX
Joon Oh Park
Metastatic Pancreatic Cancer
12/22
12/23
NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1b
24
RoW
Vactosertib, TEW-7197
Samsung Medical Center
Pancreas Cancer
12/22
03/23
NCT02930902: Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed
1b
9
US
Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Paricalcitol, Compound 49510, Zemplar, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
01/23
01/23
PanCAN-SR1, NCT04581343: A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Checkmark Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Nov 2022 - Nov 2022: Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Active, not recruiting
1b
10
US
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine, Ilaris, Abraxane
Pancreatic Cancer Action Network, Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
03/23
08/23
NCT05557851: Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
1b
36
RoW
Minnelide
Minneamrita Therapeutics LLC
Metastatic Adenocarcinoma of the Pancreas
06/24
12/24
NCT03554044: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Active, not recruiting
1b
20
US
Anastrozole, Arimidex, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC, OncoVEXGM-CSF, Tamoxifen, Nolvadex, Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin
University of California, San Francisco, Amgen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
04/25
04/25
OMO-103-02, NCT06059001: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Recruiting
1b
18
Europe
OMO-103, Nab-Paclitaxel, Gemcitabine
Peptomyc S.L.
Metastatic Pancreatic Cancer
12/25
03/26
ACTRN12623000223639: A safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)

Recruiting
1
30
 
Warpnine Incorporated, Warpnine Incorporated
Cancer
 
 
ChiCTR-ONC-08000162: Combination chemotherapy with gemcitabine and cisplatin plus recombinant endostatin (endostar) and maintenance therapy with endostar in stage IIIB and IV NSCLC

Completed
1
200
 
administration of gemcitabine with cisplatin chemotherapy plus endostar
West China Hospital, Sichuan University; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company
late stage of NSCLC
 
 
NCT00878163: GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Active, not recruiting
1
55
US
Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride, CP-358, Cp-358,774, OSI-774, Tarceva, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
01/13
03/25
NCT01660971: Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
19
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Erlotinib Hydrochloride, CP-358, Cp-358,774, OSI-774, Tarceva, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011
National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
09/17
03/25
NCT01916551: A Dose Escalation Trial of Wee1 Inhibitor MK1775

Not yet recruiting
1
70
US
Gemcitabine, Gemzar, MK-1775, Wee1 inhibitor, Radiation, IMRT
University of Michigan Cancer Center
ADENOCARCINOMA OF THE PANCREAS
10/18
10/19
NCT01852890: Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Active, not recruiting
1
16
US
Ascorbate, Ascorbic Acid, Vitamin C, Gemcitabine, Gemzar, Radiation therapy, External beam radiation therapy, Intensity modulated radiation therapy, IMRT
Joseph J. Cullen, Holden Comprehensive Cancer Center, Gateway for Cancer Research
Pancreatic Neoplasms
01/19
01/26
NCT02009449: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Checkmark In combination with pembrolizumab/ nivolumab for advanced RCC
Sep 2019 - Sep 2019: In combination with pembrolizumab/ nivolumab for advanced RCC
Checkmark Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Checkmark From AM0010/AM0010 + anti-PD-1 in NSCLC at ESMO 2017 [screenshot]
More
Active, not recruiting
1
350
US
Pegilodecakin, LY3500518, AM0010, PEGylated recombinant human Interleukin-10, PEG-rHuIL-10, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, Taxol or taxotere and paraplatin or platinol, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), Eloxatin®/Leucovorin/5-FU, gemcitabine/nab-paclitaxel, Gemzar/Abraxane ABI-007, Capecitabine, Xeloda, Pazopanib, GW786034, Pembrolizumab, Keytruda, MK-3475, Paclitaxel, nivolumab, Keytruda, Gemcitabine/carboplatin, gemzar/paraplatin
Eli Lilly and Company, ARMO BioSciences
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
02/19
08/24
NCT02495896: Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Terminated
1
61
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, nab-paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, protein-bound paclitaxel, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
University of Southern California, National Cancer Institute (NCI), Vasgene Therapeutics, Inc
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
05/19
05/19
2017-003935-12: A phase 1 trial to assess the safety, tolerability and anti-tumor activity of increasing doses of the drugs AZD6738 and gemcitabine in combination.

Not yet recruiting
1
55
Europe
Gemcitabine, AZD6738, L01BC05, Powder for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Gemcitabine
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca
Locally advanced or metastatic solid tumour., Solid tumour cancer (any type of cancer apart from leukaemia or lymphoma) which has spread., Diseases [C] - Cancer [C04]
 
 
NCT01803152: Dendritic Cell Vaccine for Children and Adults With Sarcoma

Active, not recruiting
1
19
US
Dendritic Cells Vaccine, DC Vaccine, Lysate of Tumor, Lysate, Tumor Lysate, Gemcitabine, Gemzar, Imiquimod, Aldara, Leukapheresis, Pheresis
Macarena De La Fuente, MD
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
09/19
07/24
ACTRN12618000804280: CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Active, not recruiting
1
29
 
DrugCendR Australia Pty Ltd, DrugCendR Australia Pty Ltd
Pancreatic cancer
 
 
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Active, not recruiting
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
06/24
NCT03252808: Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Active, not recruiting
1
36
Japan
TBI-1401(HF10), HF10, canerpaturev, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, TS-1, Tegafur-gimeracil-oteracil potassium
Takara Bio Inc.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
02/20
03/35
NCT02937272: A Study of LY3200882 in Participants With Solid Tumors

Active, not recruiting
1
223
Europe, Canada, Japan, US, RoW
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Eli Lilly and Company
Solid Tumor
02/20
08/25
ChiCTR-OIN-17011333: Clinical research of S-1 alone and S-1 plus gemcitabine for patients with advanced pancreatic cancer

Not yet recruiting
1
50
 
S-1 ;S-1 combined with gemcitabine
The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University, self-financing
pancreatic cancer
 
 
NCT02336087: Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Active, not recruiting
1
21
US
Gemcitabine Hydrochloride, dFdC, dFdCyd, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane, Metformin Hydrochloride, Glucophage, Metformin HCl, Therapeutic Dietary Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
City of Hope Medical Center, National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
10/20
12/24
ChiCTR1900027833: Gemcitabine/nab-paclitaxel/S-1 triple regimen for patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase I study

Recruiting
1
15
 
Initially treated patients with locally advanced or advanced pancreatic cancer will receive gemcitabine, nab-paclitaxel, and S-1 triple therapy chemotherapeutic regimen.
West China Hospital, Sichuan University; West China Hospital, Sichuan University, No
pancreatic cancer
 
 
ChiCTR2100043743: The efficacy and safety of PD-1 monoclonal antibody plus neoadjuvant chemotherapy with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma: a phase Ib clinical trial

Recruiting
1
20
 
Three cycles of PD-1 monoclonal antibody plus neoadjuvant chemotherapy with gemcitabine and cisplatin
The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, Shanghai Junshi Biomedical Technology Co., Ltd
Head and neck squamous cell carcinoma
 
 
NCT04046887: Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Terminated
1
14
US
Lonsurf, Gemcitabine, Nab-Paclitaxel
Patrick Joseph Loehrer Sr., Indiana University, Taiho Oncology, Inc.
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
05/21
10/23
NCT03703063: Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Recruiting
1
30
US
Gemcitabine, Gemzar, nab paclitaxel, Abraxane, Onivyde, Leucovorin, 5-fu
Benaroya Research Institute
Pancreatic Adenocarcinoma
09/21
09/22
NCT04707118: Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Not yet recruiting
1
106
RoW
cisplatin+Nab-paclitaxel+GEM, Nab-paclitaxel+GEM
Fudan University
Advanced Pancreatic Cancer
12/21
12/22
NCT04073784: Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Active, not recruiting
1
41
RoW
Gemcitabine combined with Aptinib and Toripalimab
Sun Yat-sen University
Nasopharyngeal Carcinoma
04/22
04/24
NCT04282070: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
1
91
RoW
SHR-1701, SHR-1701 Injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin Injection, Albumin Paclitaxel, nab-Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
04/22
12/22
NCT04156828: Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Terminated
1
12
US
Copanlisib, 1032568-63-0, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Gemcitabine, dFdCyd, Difluorodeoxycytidine, 1-(2-Oxo-4-amino-1, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Nealorin, Novoplatinum, Paraplatin, Paraplatine, Platinwas, Ribocarbo, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin Depot, Auricularum, Auxiloson, Baycadron, Baycuten, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone, Deltafluorene, Desameton, Dexa-Mamallet, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Rituximab, 174722-31-7, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, rituximab-abbs, RTXM83, Truxima, Pegfilgrastim, 208265-92-3, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Nyvepria, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Udenyca, Ziextenzo
University of Washington, Bayer
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
04/22
06/23
NCT03703089: Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Recruiting
1
21
US
Gemcitabine, GEMZAR, nab-paclitaxel, Abraxane
Benaroya Research Institute
Pancreatic Adenocarcinoma
05/22
05/23
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
NCT03884556: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Hourglass Jan 2022 - Dec 2022 : Early proof of concept data from P1/1b trial for solid tumors
Completed
1
56
US
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Trishula Therapeutics, Inc.
Solid Tumor, Lymphoma
11/22
09/23
NCT04306900: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Completed
1
185
US, RoW
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Trishula Therapeutics, Inc., AbbVie
Solid Tumor, Adult
11/22
03/24
NCT03251313: PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Active, not recruiting
1
31
RoW
JS001 120mg+GP, JS001 240mg+GP, JS001 480mg+GP, GP followed by JS001
Fudan University
Triple Negative Breast Cancer
12/22
12/22
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
NCT04523987: A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1
10
RoW
Ciprofloxacin
National University Hospital, Singapore
Metastatic Pancreatic Ductal Adenocarcinoma
02/23
02/24
SGNS40-001, NCT02376699: Safety Study of SEA-CD40 in Cancer Patients

Checkmark Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Jan 2022 - Jan 2022: Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Terminated
1
159
US
Intravenous (IV) SEA-CD40, SEA-CD40, Pembrolizumab, Keytruda, Subcutaneous (SC) SEA-CD40, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Seagen Inc., Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
03/23
04/23
NCT03435250: Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Hourglass Apr 2021 - Dec 2021 : From trial for advanced solid tumors or lymphoma with MTAP loss
Terminated
1
123
Europe, US
AG-270, MAT2A inhibitor, docetaxel, Taxotere®, nab-paclitaxel, Abraxane®, gemcitabine, Gemzar®
Institut de Recherches Internationales Servier
Advanced Solid Tumors, Lymphoma
04/23
04/23
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Active, not recruiting
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
10/24
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05299164: GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Active, not recruiting
1
18
RoW
Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4
Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd.
Non Hodgkin Lymphoma
12/23
12/25
MASCT-I, NCT03034304: A Phase I Clinical Study for Evaluating the Safety and Efficacy of in Patients With Advanced Solid Tumors

Recruiting
1
193
RoW
MASCT-I, Ifosfamide, PD1 antibody, Adriamycin, Gemcitabine, Cisplatin, Carboplatin
SYZ Cell Therapy Co..
Advanced Solid Tumors
07/23
07/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23
NCT04634539: Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Active, not recruiting
1
18
US
Gemcitabine, Nab-paclitaxel, L-glutamine, Endari
Jun Gong, MD, Emmaus Medical, Inc.
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
07/23
07/25
NCT04802980: A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Recruiting
1
72
RoW
HB002.1T, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin
Huabo Biopharm Co., Ltd.
Solid Tumor
07/23
09/23
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Not yet recruiting
1
24
NA
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
08/23
08/23
GAS, NCT06229496: Dose Escalation and Dose Expansion Study of in Subjects With Metastatic Pancreatic Adenocarcinoma

Recruiting
1
70
RoW
Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA), Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA), Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)
Chang Gung Memorial Hospital
Metastatic Pancreatic Adenocarcinoma
07/26
07/26
KEYNOTE-A62, NCT04336098: Study of SRF617 in Patients With Advanced Solid Tumors

Completed
1
85
Canada, US
SRF617, Gemcitabine, Gemzar®, Albumin-Bound Paclitaxel, Abraxane®, Pembrolizumab, Keytruda®
Coherus Biosciences, Inc., Surface Oncology, Merck Sharp & Dohme LLC
Advanced Solid Tumor
08/23
08/23
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
ATRiUM, NCT03669601: AZD6738 & Gemcitabine as Combination Therapy

Recruiting
1
55
Europe
AZD6738, Gemcitabine, Gemzar
CCTU- Cancer Theme, AstraZeneca
Cancer
09/23
09/24
NCT05193604: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Terminated
1
29
RoW
TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection, Paclitaxel for injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pancreatic Carcinoma
11/23
11/23
MAGNETIC, NCT05147272: Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Active, not recruiting
1
104
Europe, Canada, US
RP-6306 (oral PKMYT1 inhibitor), Gemcitabine (IV)
Repare Therapeutics
Adult Solid Tumor
12/24
04/25
NCT03507491: Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Active, not recruiting
1
24
US
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Emory University, Celgene Corporation
Cancer
06/24
06/24
NCT04037527: Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Suspended
1
27
US
Gemcitabine, Docetaxel, Taxotere, Radiation, Surgical Resection, Blood draws
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Soft Tissue Sarcoma
09/24
09/24
NCI-2016-01913, NCT02996825: Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed
1
44
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
02/24
02/24
NCT02627443: Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
1
31
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
11/24
11/24
NCT04733027: First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)

Recruiting
1
87
Europe
Dose escalation, first-in-human phase I clinical trial with an Expansion phase
Institut Curie
Metastatic Solid Tumor Cancer
12/24
12/24
NCT02671890: Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Active, not recruiting
1
16
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Disulfiram, Antabuse, DS, Tetraethylthioperoxydicarbonic Diamide, Teturamin, TTD, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm, Stage IV Pancreatic Cancer AJCC v8
12/24
05/25
NCT02885974: Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

Active, not recruiting
1
15
US
Celecoxib, Gemcitabine, Cisplatin
Baylor College of Medicine
Bladder Cancer
03/24
09/26
NCT05065736: Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Recruiting
1
4
US
18F-Clofarabine
Omar Mian
Metastatic Cancer, Carcinoma, Adenocarcinoma
06/24
12/24
NCT06164327: Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
75
RoW
BEBT-908 for Injection, CUDC-908, Rituximab Injection, IDEC-C2B8, Gemcitabine Hydrochloride for Injection, NSC 613327, Oxaliplatin Injection, NSC 266046, Etoposide Injection, VP-16213, Ifosfamide for Injection, NSC109724, Carboplatin Injection, NSC 241240
BeBetter Med Inc
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
10/25
11/25
HIPEC, NCT01970722: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Active, not recruiting
1
40
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery
City of Hope Medical Center, National Cancer Institute (NCI)
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
12/24
12/24
NCT06181032: A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Recruiting
1
35
RoW
Adebrelimab, SHR-1316, Apatinib, Gemcitabine, Cisplatin
First Affiliated Hospital of Fujian Medical University
Biliary Tract Malignancies
02/29
02/29
NCT03484299: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
1
20
US
Irreversible Electroporation (IRE), Gemcitabine, FOLFIRINOX
University of Louisville
Pancreas Cancer
12/23
07/24
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT04491942: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Active, not recruiting
1
74
Canada, US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011
National Cancer Institute (NCI)
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
06/25
06/25
SELISARC, NCT04595994: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Recruiting
1
14
Europe
Selinexor, Gemcitabine
Grupo Espanol de Investigacion en Sarcomas
Sarcoma,Soft Tissue
11/25
05/26
NCT06199466: A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Recruiting
1
64
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-paclitaxel, Paclitaxel, Abraxane, ABI-007, YL-13027
M.D. Anderson Cancer Center, 280Bio Inc
Metastatic Pancreatic Cancer
01/27
01/27
NCI-2017-01957, NCT03321643: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Active, not recruiting
1
24
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
06/25
06/25
NCI10208, NCT03816358: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting
1
74
Canada, US
Anetumab Ravtansine, BAY 94-9343, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/25
01/25
ZN-c3-002, NCT04516447: A Study of ZN-c3 in Patients With Ovarian Cancer

Jul 2023 - Dec 2023: Data from trial in combination with chemotherapy for platinum-resistant ovarian cancer
Recruiting
1
140
Europe, US, RoW
ZN-c3, Study drug, Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/24
02/27
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Recruiting
1
264
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
10/26
NCT06204614: Drug Screening Using IMD in Bladder Cancer

Not yet recruiting
1
18
US
Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab
Brigham and Women's Hospital
Muscle Invasive Bladder Urothelial Carcinoma
07/24
07/25
NCT05285358: Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Recruiting
1
12
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
10/28
10/28
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
NCT01104350: Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Active, not recruiting
1
19
US
external radiation therapy with gemcitabine
Memorial Sloan Kettering Cancer Center
Bladder Cancer
04/25
04/25
NCT06326736: Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Recruiting
1
12
RoW
Surgery, Surgical resection, Camrelizumab, PD-1 inhibitor, SJ-Neo006, Neoantigen mRNA Vaccines, Gemcitabine+Abraxane, chemotherapy
Jinling Hospital, China, Jiangsu Synthgene Biotechnology Co.Ltd.
Pancreatic Cancer
12/25
12/26
NCT06454383: Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting
1
19
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diagnostic Imaging, Medical Imaging, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Leflunomide, Arava, SU101, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
11/26
11/26
CHASe-PDAC, NCT06393400: CHemotherapy And Stool Transplant in PDAC

Not yet recruiting
1
20
Canada
Fecal Microbiota Transplantation, PEG3350, Gemcitabine, nab-Paclitaxel
John Lenehan
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
02/28
02/28
NCT06360354: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Recruiting
1
282
US
AMG 193, Gemcitabine, Nab-paclitaxel, Cisplatin, Pembrolizumab, Modified FOLFIRINOX
Amgen
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
11/25
11/27
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
NCT04616534: Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Active, not recruiting
1
64
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine
National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
07/24
07/24
NCT06447662: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Not yet recruiting
1
330
US
PF-07934040, PF-4040, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Cetuximab, Erbitux, Fluorouracil, 5-FU, 5-fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium, Bevacizumab, Zirabev, Avastin, Pembrolizumab, Pembro, Lambrolizumab, MK-3475, Keytruda, pemetrexed, Alimta, Cisplatin, Platinol, Cisplatinum, neoplatin, Paclitaxel, Taxol, Onxol, Carboplatin, Paraplatin, Stricarb
Pfizer
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
07/27
07/28
NCT03259503: Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Active, not recruiting
1
50
US
Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
07/24
07/24
NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Not yet recruiting
1
12
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus
M.D. Anderson Cancer Center, Aadi Bioscience
Leiomyosarcoma, Soft-tissue Sarcomas
02/29
02/31
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
Breast 54, NCT04796220: Focused Ultrasound and Gemcitabine in Breast Cancer

Recruiting
1
48
US
Gemcitabine, Gemzar, Focused Ultrasound, EchoPulse, Gemcitabine and Focused Ultrasound, Gemzar, EchoPulse
Patrick Dillon, MD
Breast Cancer, Breast Neoplasms
08/25
01/26
NCT04634227: Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Recruiting
1
40
US
Ascorbate
Mohammed Milhem, MBBS, University of Iowa
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
08/24
08/24
IntenSify, NCT05494866: A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
18
Europe
Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
German Cancer Research Center, University Hospital Heidelberg
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasm
08/24
02/25
NCT00479128: Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Active, not recruiting
1
80
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Doxorubicin, Adriamycin, AD, Hydroxydaunomycin hydrochloride
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Solid Tumor, Urethral Cancer
09/24
09/24
NCT04522050: Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Recruiting
1
65
RoW
Gemcitabine combined with cisplatin induction chemotherapy, concurrent chemoradiotherapy with gemcitabine
Fifth Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma
10/24
12/24
NCT04338763: RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Recruiting
1
48
RoW
RP72, Rise Prot-72, Gemcitabine
Rise Biopharmaceuticals, Inc., T-TOP Clinical Research Co., Ltd.
Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
10/24
12/25
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
CCODG-NSCLC, NCT02889666: A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Recruiting
1
500
RoW
Cisplatin, Platinol, Carboplatin, Paraplatin, Docetaxel, Taxotere, Gemcitabine/Carboplatin, Gemzar/Paraplatin, Gemcitabine/Cisplatin, Gemzar/Platinol, Docetaxel/Oxaliplatin, Taxotere/Eloxatin, Docetaxel/Carboplatin, Taxotere/Paraplatin, Placebo
Shanghai Jiao Tong University School of Medicine, Shanghai 10th People's Hospital, Jilin University, Jiangxi Provincial Cancer Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine
Recurrent Non-small Cell Lung Cancer
12/26
12/27
 

Download Options